The goal of the Career Development Program is to prepare physicians and scientists for independent careers in translational research in sarcoma. It is our hope that the women and men funded through this process will spend their professional lifetimes conducting translational research specifically in this set of diseases and that they will become leaders in their fields of interest. Memorial Sloan-Kettering Cancer Center (MSKCC) is ideally suited for this task, with substantial physical and faculty resources and more than a century of experience training physicians and scientists of the highest quality. Our institutional environment includes a K12 for translational science training and a K30 for the training of clinical investigators. In the Career Development Program, we plan to enhance the formal training programs that already exist at MSKCC. We will encourage more physicians to focus on translational research in sarcoma and will similarly strive to attract basic scientists to devote postdoctoral fellowship training to this quickly evolving field. We will also provide partial support for two new junior faculty investigators every 2 to 3 years who commit their careers to translational research in sarcoma. In our efforts to recruit these investigators, we will draw upon existing programs at MSKCC that recruit, train, and mentor postgraduate scientists and physician-scientists. We will budget at least $150,000 yearly for this program, including $50,000 from the SPORE award itself and at least $100,000 in funds pledged by MSKCC. To continually educate both trainees and SPORE staff, we will utilize regularly scheduled conferences, data presentations by members of the SPORE research projects and cores, and presentations by invited speakers. The Career Development Program will be directed by a Career Development Committee, chaired by Dr. David Spriggs and Dr. Robert Maki.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Agaram, Narasimhan P; Chen, Chun-Liang; Zhang, Lei et al. (2014) Recurrent MYOD1 mutations in pediatric and adult sclerosing and spindle cell rhabdomyosarcomas: evidence for a common pathogenesis. Genes Chromosomes Cancer 53:779-87
Antonescu, Cristina R; Chen, Hsiao-Wei; Zhang, Lei et al. (2014) ZFP36-FOSB fusion defines a subset of epithelioid hemangioma with atypical features. Genes Chromosomes Cancer 53:951-9
Kohsaka, Shinji; Shukla, Neerav; Ameur, Nabahet et al. (2014) A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet 46:595-600
Kim, Teresa S; Cavnar, Michael J; Cohen, Noah A et al. (2014) Increased KIT inhibition enhances therapeutic efficacy in gastrointestinal stromal tumor. Clin Cancer Res 20:2350-62
Qin, Li-Xuan; Breeden, Linda; Self, Steven G (2014) Finding gene clusters for a replicated time course study. BMC Res Notes 7:60
Brennan, Murray F; Antonescu, Cristina R; Moraco, Nicole et al. (2014) Lessons learned from the study of 10,000 patients with soft tissue sarcoma. Ann Surg 260:416-21; discussion 421-2
Patwardhan, Parag P; Surriga, Oliver; Beckman, Michael J et al. (2014) Sustained inhibition of receptor tyrosine kinases and macrophage depletion by PLX3397 and rapamycin as a potential new approach for the treatment of MPNSTs. Clin Cancer Res 20:3146-58
Weinreb, Ilan; Zhang, Lei; Tirunagari, Laxmi M S et al. (2014) Novel PRKD gene rearrangements and variant fusions in cribriform adenocarcinoma of salivary gland origin. Genes Chromosomes Cancer 53:845-56
Antonescu, Cristina R; Sung, Yun-Shao; Chen, Chun-Liang et al. (2014) Novel ZC3H7B-BCOR, MEAF6-PHF1, and EPC1-PHF1 fusions in ossifying fibromyxoid tumors--molecular characterization shows genetic overlap with endometrial stromal sarcoma. Genes Chromosomes Cancer 53:183-93
Lee, William; Teckie, Sewit; Wiesner, Thomas et al. (2014) PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet 46:1227-32

Showing the most recent 10 out of 37 publications